Valsartan attenuates atherosclerosis via upregulating the Th2 immune response in prolonged angiotensin II–treated ApoE–/– mice

Molecular Medicine

Volumn 21, Issue , 2015, Pages 143-153

  Meng, Kai ^a,b   Zeng, Qiutang ^b   Lu, Qinghua ^a   Lin, Yingzhong ^c   Wu, Bangwei ^b   Yu, Kunwu ^b   Dong, Zhaoqiang ^a   Zhang, Jianwei ^d   Chai, Meng ^d   Liu, Yuyang ^d   Ji, Qingwei ^b,c,d   Zhou, Yujie ^d  

^a THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c People's Hospital of the Guangxi Zhuang Autonomous Region   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; APOLIPOPROTEIN E; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 23; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 5; MONOCLONAL ANTIBODY; VALSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; LIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE REGULATION; CD4+ T LYMPHOCYTE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; MALE; MINIPUMP; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE; TH1 CELL; TH17 CELL; TH2 CELL; TREATMENT DURATION; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; ATHEROSCLEROSIS; BLOOD; BLOOD PRESSURE; BODY WEIGHT; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; INFLAMMATION; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIBODIES, MONOCLONAL; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY WEIGHT; DISEASE MODELS, ANIMAL; INFLAMMATION; INTERLEUKIN-5; LIPIDS; MALE; MICE; MICE, KNOCKOUT; PLAQUE, ATHEROSCLEROTIC; T-LYMPHOCYTE SUBSETS; TH2 CELLS; VALSARTAN;

EID: 84938898486     PISSN: 10761551     EISSN: 15283658     Source Type: Journal    
DOI: 10.2119/molmed.2014.00195     Document Type: Article

References (44)

1. Medzhitov R, et al. (2011) Highlights of 10 years of immunology in Nature Reviews Immunology. Nat. Rev. Immunol. 11:693-702.
2. Robertson AK, Hansson GK. (2006) T cells in atherogenesis: for better or for worse? Arterioscler. Thromb. Vasc. Biol. 26:2421-32.
3. Frostegård J, et al. (1999) Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis. 145:33-43.
4. Whitman SC, Ravisankar P, Elam H, Daugherty A. (2000) Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/- mice. Am. J. Pathol. 157:1819-24.
5. Mazzolai L, et al. (2004) Endogenous angiotensin II induces atherosclerotic plaque vulnerability and elicits a Th1 response in ApoE-/- mice. Hypertension. 44:277-82.
6. Cheng X, et al. (2008) Suppressive oligodeoxynucleotides inhibit atherosclerosis in ApoE(-/-) mice through modulation of Th1/Th2 balance. J. Mol. Cell Cardiol. 45:168-75.
7. Erbel C, et al. (2009) Inhibition of IL-17A attenuates atherosclerotic lesion development in apoEdeficient mice. J. Immunol. 183:8167-75.
8. Smith E, et al. (2010) Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation. 121:1746-55.
9. Butcher MJ, Gjurich BN, Phillips T, Galkina EV. (2012) The IL-17A/IL-17RA axis plays a proatherogenic role via the regulation of aortic myeloid cell recruitment. Circ. Res. 110:675-87.
10. Ait-Oufella H, et al. (2006) Natural regulatory T cells control the development of atherosclerosis in mice. Nat. Med. 12:178-80.
11. Mor A, et al. (2007) Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 27:893-900.
12. Zhong Y, et al. (2012) CD4+LAP+ and CD4+CD25+Foxp3+ regulatory T cells induced by nasal oxidized low-density lipoprotein suppress effector T cells response and attenuate atherosclerosis in ApoE-/- mice. J. Clin. Immunol. 32:1104-17
13. Yu K, et al. (2013) Thymic stromal lymphopoietin attenuates the development of atherosclerosis in ApoE-/- mice. J. Am. Heart Assoc. 2:e000391.
14. Klingenberg R, et al. (2013) Depletion of FOXP3+ regulatory T cells promotes hypercholesterolemia and atherosclerosis. J. Clin. Invest. 123:1323-34.
15. Strawn WB, Ferrario CM. (2002) Mechanisms linking angiotensin II and atherogenesis. Curr. Opin. Lipidol. 13:505-12.
16. Ferrario CM. (2002) Use of angiotensin II receptor blockers in animal models of atherosclerosis. Am. J. Hypertens. 15:9S-13S.
17. Arishiro K, et al. (2007) Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits. J. Am. Coll. Cardiol. 49:1482-9.
18. Tedgui A, Mallat Z. (2006) Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol. Rev. 86:515-81.
19. Madhur MS, et al. (2010) Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension. 55:500-7.
20. Barhoumi T, et al. (2011) T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension. 57:469-76.
21. Kassan M, Galan M, Partyka M, Trebak M, Matrougui K. (2011) Interleukin-10 released by CD4+CD25+ natural regulatory T cells improves microvascular endothelial function through inhibition of NADPH oxidase activity in hypertensive mice. Arterioscler. Thromb. Vasc. Biol. 31:2534-42.
22. Shao J, et al. (2003) Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension. 42:31-8.
23. McMurray J, et al. (2006) The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J. Am. Coll. Cardiol. 47:726-33.
24. de Gasparo M. (2000) New basic science initiatives with the angiotensin II receptor blocker valsartan. J. Renin Angiotensin Aldosterone Syst. 1:S3-5.
25. Daugherty A, Whitman SC. (2003) Quantification of atherosclerosis in mice. Methods Mol. Biol. 209:293-309.
26. Binder CJ, et al. (2004) IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J. Clin. Invest. 114:427-37.
27. Miller AM, et al. (2008) IL-33 reduces the development of atherosclerosis. J. Exp. Med. 205:339-46.
28. Methe H, et al. (2005) Enhanced T-helper-1 lymphocyte activation patterns in acute coronary syndromes. J. Am. Coll. Cardiol. 45:1939-45.
29. Ji QW, et al. (2009) Downregulation of T helper cell type 3 in patients with acute coronary syndrome. Arch. Med. Res. 40:285-93.
30. Benagiano M, et al. (2003) T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc. Natl. Acad. Sci. U. S. A. 100:6658-63.
31. Engelbertsen D, et al. (2013) T-helper 2 immunity is associated with reduced risk of myocardial infarction and stroke. Arterioscler. Thromb. Vasc. Biol. 33:637-44.
32. Tracy RP, et al. (2013) T-helper type 1 bias in healthy people is associated with cytomegalovirus serology and atherosclerosis: the Multi-Ethnic Study of Atherosclerosis. J. Am. Heart Assoc. 2:e000117.
33. Davenport P, Tipping PG. (2003) The role of interleukin- 4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am. J. Pathol. 163:1117-25.
34. Perry HM, et al. (2013) Helix-loop-helix factor inhibitor of differentiation 3 regulates interleukin-5 expression and B-1a B cell proliferation. Arterioscler. Thromb. Vasc. Biol. 33:2771-9.
35. Cardilo-Reis L, et al. (2012) Interleukin-13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype. EMBO Mol. Med. 4:1072-86.
36. McLaren JE, et al. (2010) IL-33 reduces macrophage foam cell formation. J. Immunol.185:1222-9.
37. Guzik TJ, et al. (2007) Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J. Exp. Med. 204:2449-60.
38. Marvar PJ, et al. (2012) T lymphocytes and vascular inflammation contribute to stress-dependent hypertension. Biol. Psychiatry. 71:774-82.
39. Zhang JD, et al. (2012) A novel role for type 1 angiotensin receptors on T lymphocytes to limit target organ damage in hypertension. Circ. Res. 110:1604-17.
40. Barhoumi T, et al. (2011) T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension. 57:469-76.
41. Madhur MS, et al. (2011) Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice. Arterioscler. Thromb. Vasc. Biol. 31:1565-72.
42. Kvakan H, et al. (2009) Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation. 119:2904-12.
43. Matrougui K, et al. (2011) Natural regulatory T cells control coronary arteriolar endothelial dysfunction in hypertensive mice. Am. J. Pathol. 178:434-41.
44. Ait-Oufella H, et al. (2013) Natural regulatory T cells limit angiotensin II-induced aneurysm formation and rupture in mice. Arterioscler. Thromb. Vasc. Biol. 33:2374-9.